Non-ATP Competitive Protein Kinase Inhibitors

被引:103
作者
Garuti, L. [1 ]
Roberti, M. [1 ]
Bottegoni, G. [2 ]
机构
[1] Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy
[2] Italian Inst Technol, Dept Drug Discovery & Dev, I-16163 Genoa, Italy
关键词
Allosteric; antitumor activity; inhibition; kinase; non-ATP competitive; SAR; 2,3,5-TRISUBSTITUTED PYRIDINE-DERIVATIVES; ALLOSTERIC DUAL AKT-1; AZD6244; ARRY-142886; SELECTIVE INHIBITORS; POTENT INHIBITORS; DISCOVERY; DESIGN; GROWTH; CANCER; TIE-2;
D O I
10.2174/092986710791859333
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein kinases represent an attractive target in oncology drug discovery. Most of kinase inhibitors are ATP-competitive and are called type I inhibitors. The ATP-binding pocket is highly conserved among members of the kinase family and it is difficult to find selective agents. Moreover, the ATP-competitive inhibitors must compete with high intracellular ATP levels leading to a discrepancy between IC(50)s measured by biochemical versus cellular assays. The non-ATP competitive inhibitors, called type II and type III inhibitors, offer the possibility to overcome these problems. These inhibitors act by inducing a conformational shift in the target enzyme such that the kinase is no longer able to function. In the DFG-out form, the phenylalanine side chain moves to a new position. This movement creates a hydrophobic pocket available for occupation by the inhibitor. Some common features are present in these inhibitors. They contain a heterocyclic system that forms one or two hydrogen bonds with the kinase hinge residue. They also contain a hydrophobic moiety that occupies the pocket formed by the shift of phenylalanine from the DFG motif. Moreover, all the inhibitors bear a hydrogen bond donor-acceptor pair, usually urea or amide, that links the hinge-binding portion to the hydrophobic moiety and interacts with the allosteric site. Examples of non ATP-competitive inhibitors are available for various kinases. In this review small molecules capable of inducing the DFG-out conformation are reported, especially focusing on structural feature, SAR and biological properties.
引用
收藏
页码:2804 / 2821
页数:18
相关论文
共 70 条
[1]   Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers [J].
Adjei, Alex A. ;
Cohen, Roger B. ;
Franklin, Wilbur ;
Morris, Clive ;
Wilson, David ;
Molina, Julian R. ;
Hanson, Lorelei J. ;
Gore, Lia ;
Chow, Laura ;
Leong, Stephen ;
Maloney, Lara ;
Gordon, Gilad ;
Simmons, Heidi ;
Marlow, Allison ;
Litwiler, Kevin ;
Brown, Suzy ;
Poch, Gregory ;
Kane, Katie ;
Haney, Jerry ;
Eckhardt, S. Gail .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2139-2146
[2]   Kinase inhibition with BAY 43-9006 n renal cell carcinoma [J].
Ahmad, T ;
Eisen, T .
CLINICAL CANCER RESEARCH, 2004, 10 (18) :6388S-6392S
[3]   Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERKI/2 signalling and/or strong P13K signalling in colorectal cancer cell lines [J].
Balmanno, Kathryn ;
Chell, Simon D. ;
Gillings, Annette S. ;
Hayat, Shaista ;
Cook, Simon J. .
INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (10) :2332-2341
[4]   The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901 [J].
Barrett, Stephen D. ;
Bridges, Alexander J. ;
Dudley, David T. ;
Saltiel, Alan R. ;
Fergus, James H. ;
Flamme, Cathlin M. ;
Delaney, Amy M. ;
Kaufman, Michael ;
LePage, Sophie ;
Leopold, Wilbur R. ;
Przybranowski, Sally A. ;
Sebolt-Leopold, Judith ;
Van Becelaere, Keri ;
Doherty, Annette M. ;
Kennedy, Robert M. ;
Marston, Dan ;
Howard, W. Allen, Jr. ;
Smith, Yvonne ;
Warmus, Joseph S. ;
Tecle, Haile .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (24) :6501-6504
[5]   Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors [J].
Bauer, David ;
Whittington, Douglas A. ;
Coxon, Angela ;
Bready, James ;
Harriman, Shawn P. ;
Patel, Vinod F. ;
Polverino, Anthony ;
Harmange, Jean-Christophe .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (17) :4844-4848
[6]   Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies [J].
Bikker, Jack A. ;
Brooijmans, Natasja ;
Wissner, Allan ;
Mansour, Tarek S. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (06) :1493-1509
[7]   Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model [J].
Bilodeau, Mark T. ;
Balitza, Adrienne E. ;
Hoffman, Jacob M. ;
Manley, Peter J. ;
Barnett, Stanley F. ;
Defeo-Jones, Deborah ;
Haskell, Kathleen ;
Jones, Raymond E. ;
Leander, Karen ;
Robinson, Ronald G. ;
Smith, Anthony M. ;
Huber, Hans E. ;
Hartman, George D. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (11) :3178-3182
[8]   A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding [J].
Bogoyevitch, Marie A. ;
Fairlie, David P. .
DRUG DISCOVERY TODAY, 2007, 12 (15-16) :622-633
[9]   Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR:: Synthesis, SAR, and pharmacokinetic properties [J].
Choquette, Deborah ;
Teffera, Yohannes ;
Polverino, Anthony ;
Harmange, Jean-Christophe .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (14) :4054-4058
[10]   In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase [J].
Chung, Eun Joo ;
Brown, Aaron P. ;
Asano, Hiroaki ;
Mandler, Mariana ;
Burgan, William E. ;
Carter, Donna ;
Camphausen, Kevin ;
Citrin, Deborah .
CLINICAL CANCER RESEARCH, 2009, 15 (09) :3050-3057